Related Experiment Video
Updated: Jul 28, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Zhuojun Xie1, Zirui Zhou1, Shuxian Yang1
1State Key Laboratory of Oral Diseases and National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, No. 14, Section 3, South Renmin Road, Sichuan, 610041, Chengdu, China.
Abstract:
The tumor microenvironment (TME) is crucial to neoplastic processes, fostering proliferation, angiogenesis and metastasis. Epigenetic regulations, primarily including DNA and RNA methylation, histone modification and non-coding RNA, have been generally recognized as an essential feature of tumor malignancy, exceedingly contributing to the dysregulation of the core gene expression in neoplastic cells, bringing about the evasion of immunosurveillance by influencing the immune cells in TME. Recently, compelling evidence have highlighted that clinical therapeutic approaches based on epigenetic machinery modulate carcinogenesis through targeting TME components, including normalizing cells' phenotype, suppressing cells' neovascularization and repressing the immunosuppressive components in TME. Therefore, TME components have been nominated as a promising target for epigenetic drugs in clinical cancer management. This review focuses on the mechanisms of epigenetic modifications occurring to the pivotal TME components including the stroma, immune and myeloid cells in various tumors reported in the last five years, concludes the tight correlation between TME reprogramming and tumor progression and immunosuppression, summarizes the current advances in cancer clinical treatments and potential therapeutic targets with reference to epigenetic drugs. Finally, we summarize some of the restrictions in the field of cancer research at the moment, further discuss several interesting epigenetic gene targets with potential strategies to boost antitumor immunity.
Insights
Epigenetic modifications in the tumor microenvironment (TME) drive cancer progression and immune evasion. Targeting TME components with epigenetic drugs offers promising new cancer therapies.
Area of Science:
- Oncology
- Epigenetics
- Cancer Immunology
Background:
- The tumor microenvironment (TME) is integral to cancer development, promoting proliferation, angiogenesis, and metastasis.
- Epigenetic regulations (DNA/RNA methylation, histone modification, non-coding RNA) are key to tumor malignancy and immune evasion.
- Epigenetic mechanisms influence immune cells within the TME, contributing to immunosuppression.
Purpose of the Study:
- To review epigenetic modifications in pivotal TME components (stroma, immune, myeloid cells) across various tumors.
- To elucidate the correlation between TME reprogramming, tumor progression, and immunosuppression.
- To summarize current advances in epigenetic-based cancer therapies and future strategies.
Main Methods:
- Literature review focusing on epigenetic mechanisms within the TME.
- Analysis of recent studies (last five years) on epigenetic modifications in stromal, immune, and myeloid cells.
- Synthesis of findings on the role of epigenetics in TME reprogramming and cancer progression.
Main Results:
- Epigenetic reprogramming of TME components is tightly linked to tumor progression and immune evasion.
- Epigenetic drugs can modulate TME components, normalizing cell phenotypes, suppressing neovascularization, and reducing immunosuppression.
- TME components are identified as promising targets for epigenetic drugs in clinical cancer management.
Conclusions:
- Epigenetic modifications significantly impact the TME, influencing tumor behavior and immune response.
- Targeting the TME with epigenetic therapies holds potential for novel cancer treatment strategies.
- Further research into specific epigenetic targets is needed to enhance antitumor immunity.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Epigenetic Regulation
X-chromosome...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Tumor Immunotherapy

